PRESTIGE CONSUMER HEALTHCARE INC. Cash and Restricted Cash
PRESTIGE CONSUMER HEALTHCARE INC. (PBH) had Cash and Restricted Cash of $89.13 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $89.13M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $63.87M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $62.37M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $119.11M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $89.13M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $63.87M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $62.37M 10-Q · filed 2026-02-05 |
| 2025-09-30 | $119.11M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $139.50M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $97.88M 10-Q · filed 2026-08-06 |
| 2024-12-31 | $50.87M 10-Q · filed 2026-02-05 |
| 2024-09-30 | $51.54M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $34.26M 10-Q · filed 2025-08-07 |
| 2024-03-31 | $46.47M 10-K · filed 2026-05-14 |
| 2023-12-31 | $63.62M 10-Q · filed 2025-02-06 |
| 2023-09-30 | $60.07M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $54.58M 10-Q · filed 2024-08-08 |
| 2023-03-31 | $58.49M 10-K · filed 2026-05-14 |
| 2022-12-31 | $86.36M 10-Q · filed 2024-02-08 |
| 2022-09-30 | $42.44M 10-Q · filed 2023-11-02 |
| 2022-06-30 | $35.87M 10-Q · filed 2023-08-03 |
| 2022-03-31 | $27.18M 10-K · filed 2025-05-09 |
| 2021-12-31 | $21.02M 10-Q · filed 2023-02-02 |
| 2021-09-30 | $42.82M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $163.62M 10-Q · filed 2022-08-04 |
| 2021-03-31 | $32.30M 10-K · filed 2024-05-15 |
| 2020-12-31 | $62.10M 10-Q · filed 2022-02-03 |
| 2020-09-30 | $26.60M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $57.94M 10-Q · filed 2021-08-05 |
| 2020-03-31 | $94.76M 10-K · filed 2023-05-05 |
| 2019-12-31 | $28.59M 10-Q · filed 2021-02-04 |
| 2019-09-30 | $27.91M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $29.04M 10-Q · filed 2020-08-06 |
| 2019-03-31 | $27.53M 10-K · filed 2022-05-06 |
| 2018-12-31 | $24.67M 10-Q · filed 2020-02-06 |
| 2018-09-30 | $36.91M 10-Q · filed 2019-10-31 |
| 2018-06-30 | $34.27M 10-Q · filed 2019-08-01 |
| 2018-03-31 | $32.55M 10-K · filed 2021-05-07 |
| 2017-03-31 | $41.85M 10-K · filed 2020-05-08 |
| 2016-03-31 | $27.23M 10-K · filed 2019-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |